Diagnostic Accuracy of Procalcitonin upon Emergency Department Admission during SARS-CoV-2 Pandemic
Authors:
- Stefano MalinverniSMStefano Malinverni
- Silvia LazzaroniSLSilvia Lazzaroni
- Maïa NuňezMNMaïa Nuňez
- Thierry PreseauTPThierry Preseau
- Frédéric CottonFCFrédéric Cotton
- Delphine MartinyDMDelphine Martiny
- Fatima BouazzaFBFatima Bouazza
- Vincent CollotVCVincent Collot
- Deborah KonopnickiDKDeborah Konopnicki
- Stéphane AlardSAStéphane Alard
- Magali BartiauxMBMagali Bartiaux
Open Access
- 23 August 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (9) , 1141
Abstract
Introduction: Procalcitonin is a marker for bacterial diseases and has been used to guide antibiotic prescription. Procalcitonin accuracy, measured at admission, in patients with community-acquired pneumonia (CAP), is unknown in the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Objectives: To evaluate the diagnostic accuracy of procalcitonin to assess the need for antibiotic treatment in patients with CAP presenting to the emergency department during the SARS-CoV-2 pandemic. Methods: We performed a real-world diagnostic retrospective accuracy study of procalcitonin in patients admitted to the emergency department. Measures of diagnostic accuracy were calculated based on procalcitonin results compared to the reference standard of combined microbiological and radiological analysis. Sensitivity, specificity, positive and negative predictive values, and area under (AUC) the receiver-operating characteristic (ROC) curve were calculated in two analyses: first assessing procalcitonin ability to differentiate microbiologically proven bacteria from viral CAP and then clinically diagnosed bacterial CAP from viral CAP. Results: When using a procalcitonin threshold of 0.5 ng/mL to identify bacterial etiology within patients with CAP, we observed sensitivity and specificity of 50% and 64.1%, and 43% and 82.6%, respectively, in the two analyses. The positive and negative predictive values of a procalcitonin threshold of 0.5 ng/mL to identify patients for whom antibiotics should be advised were 46.4% and 79.7%, and 48.9% and 79% in the two analyses, respectively. The AUC for the two analyses was 0.60 (95% confidence interval [CI] 0.52–0.68) and 0.62 (95% CI, 0.55–0.69). Conclusions: Procalcitonin measured upon admission during the SARS-CoV-2 pandemic should not guide antibiotic treatment in patients with CAP.Keywords
This publication has 30 references indexed in Scilit:
- Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysisThorax, 2015
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. AdultsNew England Journal of Medicine, 2015
- Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year studyJournal of Infection, 2013
- Guidelines for the management of adult lower respiratory tract infections - Full versionClinical Microbiology and Infection, 2011
- Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot studyJournal of Critical Care, 2011
- Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre studyIntensive Care Medicine, 2011
- Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract InfectionsJAMA, 2009
- Procalcitonin Guidance of Antibiotic Therapy in Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Usefulness of Procalcitonin as a Marker of Systemic Infection in Emergency Department Patients: A Prospective StudyClinical Infectious Diseases, 2002
- High serum procalcitonin concentrations in patients with sepsis and infectionThe Lancet, 1993